CD44 and neoplasm: Phenotypic profiling also showed that the percentages of CD69+, CD44+, and DNAM+ cells were significantly increased in all immune effector compartments analyzed (CD8+ T-cells, CD4+FoxP3- T-cells, and NK cells), indicating that the drug enhances both adaptive and innate anti-tumor immune responses in the 4T1.2 TNBC model.